A New Kind of Clinical Research Requires a New Kind of CRO:
Powered by Data and Built to Perform.
A New Kind of CRO That Is Ready for…
Defining crucial solutions for digital therapeutics
Running Digital Therapeutics trials challenge traditional processes and demands a CRO with experience and adaptability to navigate regulations, design studies and quality data to accelerate development.
Is your CRO ready to answer your questions on digital therapeutics?
The new realities of precision medicine
Technology has radically altered the path of treatment. Cheaper genetic sequencing and the advent of new biomarkers has opened the door to personalized, targeted medicine, but also to a new reality of difficult recruitment and extremely complex protocols.
Is your CRO ready for the new realities of precision medicine?
The unique challenges of rare disease trials
Treatments for rare disease make up more than half of annual drug approvals. These clinical trials bring new challenges with patient populations that are small and globally dispersed. Successfully completing these trials requires a partner designed to navigate these complexities.
Is your CRO ready for the unique challenges of rare disease trials?
What Defines A New Kind of CRO?
A New Kind of CRO That Is Ready for…
Defining crucial solutions for digital therapeutics
Running Digital Therapeutics trials challenge traditional processes and demands a CRO with experience and adaptability to navigate regulations, design studies and quality data to accelerate development.
Is your CRO ready to answer your questions on digital therapeutics?
The new realities of precision medicine
Technology has radically altered the path of treatment. Cheaper genetic sequencing and the advent of new biomarkers has opened the door to personalized, targeted medicine, but also to a new reality of difficult recruitment and extremely complex protocols.
Is your CRO ready for the new realities of precision medicine?
The unique challenges of rare disease trials
Treatments for rare disease make up more than half of annual drug approvals. These clinical trials bring new challenges with patient populations that are small and globally dispersed. Successfully completing these trials requires a partner designed to navigate these complexities.
Is your CRO ready for the unique challenges of rare disease trials?
What Defines A New Kind of CRO?
A New Kind of CRO That Is Ready for…
Defining crucial solutions for digital therapeutics
Running Digital Therapeutics trials challenge traditional processes and demands a CRO with experience and adaptability to navigate regulations, design studies and quality data to accelerate development.
Is your CRO ready to answer your questions on digital therapeutics?
The new realities of precision medicine
Technology has radically altered the path of treatment. Cheaper genetic sequencing and the advent of new biomarkers has opened the door to personalized, targeted medicine, but also to a new reality of difficult recruitment and extremely complex protocols.
Is your CRO ready for the new realities of precision medicine?
The unique challenges of rare disease trials
Treatments for rare disease make up more than half of annual drug approvals. These clinical trials bring new challenges with patient populations that are small and globally dispersed. Successfully completing these trials requires a partner designed to navigate these complexities.
Is your CRO ready for the unique challenges of rare disease trials?
What Defines A New Kind of CRO?
Programs, Not Trials
You think in terms of programs and pipelines, not individual trials. We do, too. We seek to support your entire development program, not just the trial in front of us.
We don’t allow tunnel vision to set in. Biorasi is constantly looking for ways to help you optimize and improve your entire therapeutic pipeline. From finding new regulatory pathways and venues, to identifying follow-on indications.
Patients, Not Sites
Your challenge is recruiting the right patients, not finding the right sites. Our challenge is to help you find those patients wherever they are.
Thinking in terms of patients allows us to break away from the traditional reliance on sites and go directly to where your patients are. The result is faster recruitment of higher quality patients, especially in complex and difficult to recruit trials.
Data Science, not Data Management
Your trials generate a lot of data – over 3 million individual points. But is that data being harnessed to help your trial and your program?
We leverage advanced analytics and techniques inspired by big data processing to put your clinical data to work. Instead of just collecting, we process from the beginning, giving you deep insights and a strategic advantage from the start.
Transparency, Not Reporting
Your trials run 24/7, with new activity daily. So why do you only get reports once a week, if that? Knowing that your trial is on track requires transparency unlike anything the industry has seen.
We believe that you should own your data, and should be able to access it anytime and anywhere, in real time. Our TALOS™ Control Center gives you minute by minute updates, so you know what’s happening right now, not just last week.
Structured Methodology, Not Ad-Hoc Project Management
Clinical research is becoming more complex, while the level of clinical project management stays the same. This divergence is not sustainable.
We began with a structured methodology to clinical project management and certified project management professionals. It’s why we are able to deliver your trials on time and on budget, and why we can say there are many rescues that are never rescued.
Our Core Values
Relentlessly Pioneering
____
You pioneer the science, Biorasi pioneers a better approach to clinical research. We push the boundaries of complex trials, and find ways to improve your whole program.
Insanely Efficient
____
We were built to be smarter, faster, better. More integrated in our teams and our technology. Making better use of your data. And delivering better results.
Fearlessly Accountable
____
We give our sponsors unparalleled transparency into their trials. Best in class tools like the TALOS™ Control Center give you full ownership and hold us accountable to deliver.
Partner Obsessed
____
Your success is our success, and your priorities are our priorities. We don’t believe in the terms “client” and “vendor” – we believe in building true lasting partnerships.
Talk with us
Talk with us
Talk with us
Latest Publications
Running a COVID-19 Study? Gear Up...
Biorasi is a full-service global CRO, experienced and engaged in the management of multiple coronavirus clinical trials. For companies ready to start up and initiate on potential opportunities...
COVID-19. An Impulse for a Dynamic...
The current heath emergency caused by the pandemic has placed health systems around the world under extreme pressure. One of the biggest challenges that the industry faces is...
Biorasi Kicks-Off Third COVID-19 Clinical Trial...
Biorasi Kicks-Off Third COVID-19 Clinical Trial for 2020
Biorasi Meets First Patient, First Visit...
Biorasi has met the First Patient, First Visit milestone for a dermatology trial across multiple sites during the COVID-19 pandemic.
Biorasi Welcomes Scott Nenninger as Chief...
Biorasi is proud to announce the appointment of Scott Nenninger to the position of Chief Financial Officer (CFO)
Biorasi Completes Rare Nephrology Trial During...
Biorasi has completed subject visits under Part A in a rare disease nephropathy study during the peak of the COVID-19 outbreak.
Biorasi Begins Second COVID-19 Clinical Trial...
Biorasi is proud to announce the start of a second COVID-19 clinical trial for 2020. The trial will be executed in Russia and Ukraine and will focus on...
Biorasi Starts First COVID-19 Clinical Trial...
Biorasi is proud to announce the initiation of the company’s first COVID-19 clinical trial in May 2020. The U.S.-based trial will focus on the treatment for lung injuries...
Biorasi Loves Clinical Sites
To our #sitepartners on the front lines, from all of us at Biorasi, thank you for everything you do to bring critical treatments to patients as we face...
Unflattening the Curve: Minimize the Impact...
In this time of uncertainty caused by the COVID-19 pandemic, the importance of delivering new treatments to patients as quickly as possible has never been more vital. Without...
The Focus is Digital: Biorasi Reports...
Digital technology’s presence in the healthcare industry continues to grow, expanding across diagnostic and therapeutic treatments in precision medicine. Biorasi was on-site to witness these advancements and innovations...
The Evolution of Digital Therapeutics and...
With digital therapeutics experiencing an evolution, Biorasi was on hand at DTx West 2020 to highlight the importance of evidence as a differentiator in clinical trials. Read more...
WSCS 2020 Wrap Up: Biorasi joins...
When stem cell industry innovators from across the globe congregated in Miami at the end of January 2020 to discuss the current state and future expectations of the...
Mind-Boggling Displays, Industry Trends, & other...
A team from Biorasi was at ASN Kidney Week 2019. Breakthrough research and standout presentations marked this year’s @ASNKidney Week. Check out our report for the full scoop.
NORD Breakthrough Summit: 3 Key Takeaways
A team from Biorasi joined more than 900 leaders from the FDA, NIH and the pharma and bio-pharma industries for the National Organization for Rare Disorders (NORD) &...
Strategies for Successful Digital Therapeutics Clinical...
As digital therapeutics are integrated into every aspect of the healthcare landscape, patients, payers, and providers are seeing an increasingly complex set of software-driven therapy options reaching the...
Acute Kidney Injury (AKI): Management and...
In my previous article, I explained the types, causes and symptoms of Acute Kidney Injury (AKI). Here, I’ll share how physicians treat and manage AKI, as well as...
Acute Kidney Injury (AKI): Why aggressive...
What is AKI? AKI is a sudden, reversible decline in the kidney’s glomerular filtration rate (GFR); in other words, its ability to filter metabolic waste. This kidney damage...
FSGS: A rare kidney disease without...
Researchers are studying a few new and existing drugs to treat FSGS. FSGS needs a novel medication that regulates both high body fats and inflammasome inhibition via upstream...
Is targeted gene therapy in Neurology’s...
To unlock more targeted, effective treatments, genetics researchers are exploring mutations responsible for some of the most common motor neuron diseases. These discoveries may lead to gene therapy...
Biorasi Center of Excellence Spotlight: Oncology
Biorasi’s Oncology Center of Excellence remains at the forefront of this exciting field. Our team of clinicians, program managers and other experts stay up to date on the...
How the Right Oversight Assures Clinical...
A clinical trial's operational efficiency depends on a solid oversight and response mechanism. Without vigilant monitoring, patient safety, data integrity, and the overall health of your trial come...
How to Launch a Successful, Cost-Effective...
Run a more efficient pediatric clinical trial: Although pediatric trials overall cost roughly the same as adult clinical trials according to one analysis, they generally produce a more...
Rare Disease Spotlight: C3 Glomerulopathy
C3 glomerulopathy (C3G), a rare kidney disease, affects only two or three people out of every one million. That’s only a couple people out of the entire population...
Prepare for Success: How Advance Planning...
Why Do So Many Clinical Trials Fall Behind? Clinical trials are not immune to missed deadlines and cost overruns. However, with proper advance planning, you can up the...
Determining the “ROI” of Clinical Trial...
In our rescue white paper, 3 Measures to Overcome Operational Failures, we explain our ROI concept. Early in a trial, intervention provides dramatic benefits for minimal cost. An...
The Power of Patient Registries: How...
Each year, doctors diagnose about 1,000 Americans with cystic fibrosis, a rare hereditary disease that affects […]
Is Gut Microbiome Behind Our Next...
“Microbiome” has become a consumer product buzzword, found in advertisements for soap and dozens of foods […]
Patient Recruitment Solution: How to Ease...
The numbers vary but multiple surveys confirm what we all know: patient recruitment is one of […]
Cellular Therapy in Neurological Diseases: The...
Neurological disorders and diseases affect all ages and ethnicities, and most result in long-term disability and […]
Introducing Biorasi’s Center of Excellence: Neurology...
Advances in stroke management, the first cannabinoid-derived drug approved, new therapeutics for progressive multiple sclerosis, early […]
When Virtual Trials Are Not the...
Business as usual is not an option for conducting #clinicaltrials in the wake of the #COVID19 pandemic. Customized solutions and #patientcentricity are more optimal approaches in this environment....
Dermatology Detectives: How the Right Principal...
The success of a clinical trial depends largely on the engagement and experience of the PI. In addition to identifying and recruiting patients, site PIs and their teams...
Is Your Clinical Trial in Need...
Recognizing early warning signs that your trial is in trouble, and taking quick decisive action, can often get studies back on track. Improving operations can solve most failure...
What is the Skin Microbiome?
A current Dove soap ad asks, “Is your body wash microbiome gentle?” Do you need microbiome […]
The Current Standing of Research on...
Wound healing is a complicated and dynamic process that includes multiple overlapping phases. Adequate wound […]
Post-Brexit Implications for the Pharmaceuticals Industry
On June 23, 2016, United Kingdom (UK) voters decided to leave the European Union (EU) in […]
Press Release: Leading Global CRO Hires...
Celebrated Industry Veteran to Lead Scientific, Medical, and Regulatory Affairs at Biorasi Miami, FL, Jan 29, […]
What Are The Advantages of Virtual...
In this blog post, we will try to understand Virtual Clinical Trial. As technology continues to […]
Commonalities of Rare Diseases
Collectively, rare diseases affect a huge number of people: about 25 million in the US and […]
New FDA Guidance for NASH Drug...
Just in time for our final follow-up to the two previous articles on non-alcoholic steatohepatitis (NASH), […]
Press Release: Biorasi Partners with RLH...
Florida-Based CRO seeks to expand offerings, global footprint, and headcount after successful investment transaction. Biorasi, […]
The Future of Diabetes Treatment
Type 1 diabetes affects millions of people in the US alone. What’s worse is that the […]
A Deep Dive into NASH Physiology...
In the clinical trial world, we spend a lot of time focusing on phase I-IV trials, […]
Considerations for Working with Research-Naive vs....
When recruiting patients with hard-to-enroll indications, such as rare diseases, it is sometimes necessary to dip […]
Why Aren’t There Any FDA-Approved Drugs...
The liver does many important things in the body, such as filtering of the blood and […]
10 Lessons On Success in Asia-PAC...
Earlier this year, a few of us attended DIA 2018 to represent Biorasi. While there, we […]
You’re Holding Your Eye Drops Wrong...
Last week, one of our resident experts in ophthalmology, Ignacio Handal, gave a training for some […]
A More Complete Scope for Advances...
When people think about women’s health, especially during the month of October, they may think only […]
The Politics of Investigator-Initiated Trials
Many clinical trials are initiated by a pharmaceutical company in order to generate data to submit […]
Six Things We Can Do Now...
The CKD community has set some lofty goals for the coming years. There are hopes to enroll 30% of patients with CKD in a clinical trial by 2030....
The Tumultuous History of Women’s Involvement...
Inclusion of women in clinical research has a surprisingly colorful history. As you can probably imagine, […]
Managing Alzheimer’s Trials in a Diverse...
Patients with Alzheimer’s are not treated the same everywhere. On a global level, this is immediately […]
Five New Tech Options to Use...
Have you heard of virtual clinical trials? They are trials in which patients can do most […]
How are Adaptive Trial Designs Improving...
The ability to adapt is a valued attribute in today’s constantly changing world, and clinical trial […]
Reservations Held by Referring Physicians in...
Some physicians are reluctant to participate in clinical trials as a referring physician. This is a […]
Five Lesser-known Facts about Sun Exposure
Labor Day weekend is upon us! This means that many of us will be outdoors, if […]
Don’t Let Summer Obstacles Catch You...
There are physiological and logistical challenges to running studies in the summer. We present some solutions.
Biorasi Joins Nova Southeastern University to...
Leading Florida-based Contract Research Organization Partners With University to Train Tomorrow’s Medical Research Professionals Miami, FL, […]
Eight Sponsor Essentials for a Successful...
It’s pretty common for a pharmaceutical company to have a list of demands ready when choosing a CRO partner for a clinical trial. Here at Biorasi, we have...
Using Precision Medicine in Cancer Trials
Why is it that when we take 50 people of similar height and weight and measure […]
The Future is Here for Clinical...
Mobile phone apps and wearable devices have a lot of potential to improve clinical studies. However, […]
Site Selection Process—How the balance of...
Site selection is one of the most important steps in the clinical trial process; nevertheless, it […]
An Animal Study That You Won’t...
A recent study is making history in the field of Alzheimer’s research. For a long time, […]
Biorasi Recognized for Best in Class...
Biorasi is proud to announce that leading industry publication Global Health & Pharma, also known as […]
Bolstering Enrollment in Parkinson’s Trials: Patient...
Challenges in clinical trial recruitment are particularly prevalent in PD studies of disease modification, where the population of interest is difficult to find and study design is more...
Special Considerations for Clinical Trials in...
Clinical trials in neurological diseases present a wide range of challenges and special considerations across the board. With the right experienced study team, a patient and disease pathobiology...
Non-Traditional Trial Recruitment Strategies for Non-Traditional...
Innovative and out of the box methods are often required for the recruitment of challenging populations […]
Tweaking Study Designs to Increase Enrollment...
Many of us typically think of Alzheimer’s Disease (AD) when we hear the word “dementia”. This […]
An Intern’s Glimpse into the World...
As a Master of Health Administration (MHA) candidate at the University of Miami and a Program […]
What to Look for When Selecting...
Risk-based monitoring (RBM) is heralded as the new solution to all troubles in clinical research – […]
Not Enrolling Enough? How to Rescue...
An outside rescue expert can bring a fresh set of eyes to a troubled study and help you identify the true root causes of the failure. They can...
Avoiding the Blame-Game in Rescue: Don’t...
The costs associated with missed milestones and timeline extensions are significant and can derail the trial entirely. Less than 10% of drug candidates reach approval, with sponsors often...
Stem Cells?! What are they? How...
Introduction Stem Cell Therapy is one of the most important biomedical discoveries in recent history, with […]
Holiday Hurdles in Clinical Research
With the holiday season upon us, the focus shifts from daily work tasks to planning for […]
Stem Cells: Myths and Misconceptions in...
Stem Cell therapy constitutes one of the most hailed advents in medicine for its potential in […]
Pioneers Tackling Interchangeability in Biosimilars
With a global market of USD 3.3 billion during 2016 and a forecast surpassing USD 10.5 […]
The IgAN Enigma
Immunoglobulin A (IgA) is an antibody manufactured by the body’s immune system to protect against invaders. […]
Breast Cancer Month: Better Trial Enrollment...
Despite an extremely encouraging 38% decrease in mortality since 1989, Breast Cancer remains the most common […]
Upcoming Advancements in the Treatment of...
It is estimated that the number of PD cases is likely to grow significantly as populations grow older around the world and it is predicted that PD prevalence...
Reprogramming the Mind: Virtual Reality Exposure...
According to the CDC, post-traumatic stress disorder (PTSD) is one of the most common mental disorders […]
Skin So Simple: Myth Busted
Clinical research in dermatology has a reputation for being simple and easy to conduct compared to […]
Five Signs Your Clinical Trial Needs...
Over 30% of active clinical trials are seriously behind schedule. Find out the five signs that your clinical trial needs rescue before it's too late.
Emerging Challenges in Global Clinical Studies
Clinical research is going global. This growth translates to sponsors no longer running separate studies in […]
Advances in Early Alzheimer’s Detection
The prevalence of Alzheimer’s disease (AD) is rapidly increasing as individual life spans across the world […]
Can Big Data Rescue Clinical Trials?
If you had to pick one buzzword that perfectly encapsulated the current latest and greatest in […]
3 Trends in Biosimilars: A 6-Year...
Over the next five years, the purchase and production of biosimilar drugs can expect to see […]
The Most Common Reasons for Trial...
The study is behind schedule. Enrollment is lagging. The protocol is too complicated. Approximately 80 percent of […]
Implement CDISC Standards for Faster Reporting...
The Clinical Data Interchange Standards Consortium (CDISC) created standards designed to streamline clinical research data and […]
The Promise of Biosimilar Drugs
In 2006, the European Medicines Agency granted its first approval of a biosimilar drug, the human growth hormone, […]
Creating High Performance Pharmacovigilance Teams in...
Individuals often interpret the same information and terms in dramatically different ways. Multiple factors drive these […]
Biorasi Joins GPhA Biosimilars Council to...
There is great strength in numbers, and joining forces with some of the world’s most influential […]
Clinical Research Optimized ™ Powered by...
Biorasi delivers Clinical Research Optimized ™ for Biosimilar clinical trials, proving success in some of the […]
June is Men’s Health Awareness Month
Biorasi conducts life-impacting drug studies for Men’s Health; now, if they only showed up to the […]
It’s your life; live it well....
It’s your life; live it well. Healthy Options are Key It can be hard to maintain […]
Mental Health Awareness, Part 2: Spotlight...
In September 2014, TIME called Iodine “The Yelp of Medicine,” founded by former Wired editor, Thomas […]
Mental Health Awareness, Part 1: #B4Stage4
1 in 5 American adults will have a diagnosable mental health condition in any given year. […]
Parkinson’s Disease, Part 3: The Importance...
Parkinson’s is a disease uniquely and inextricably tied to its community. Patients share symptoms, treatments, difficulties […]
Job vs. Career? The Biorasi Difference
A few years ago the news and shelves were filled with articles about Millennials entering the […]
Parkinson’s Disease, Part 2: Real-time health-tech...
As wearables gain popularity and health related applications rank higher on consumer needs; the health-tech industry […]
Parkinson’s Disease, Part 1: The Importance...
Imagine: Losing total control of physical and mental motor skills Taking simple things for granted such […]
A Perfect Match
Today we can do more on our smartphones than desktop computers could a mere ten years […]
Aiming Higher in Dermatology Clinical Trials
Let’s start with the basics. Dermatology is the branch of medicine dealing with hair, skin, nails […]
